...
首页> 外文期刊>The Journal of Antimicrobial Chemotherapy >Unique characteristics of histone deacetylase inhibitors in reactivation of latent HIV-1 in Bcl-2-transduced primary resting CD4+ Tcells
【24h】

Unique characteristics of histone deacetylase inhibitors in reactivation of latent HIV-1 in Bcl-2-transduced primary resting CD4+ Tcells

机译:组蛋白脱乙酰基酶抑制剂在Bcl-2转导的原代静息CD4 + T细胞中潜在HIV-1的激活中的独特特征

获取原文
获取原文并翻译 | 示例

摘要

Objectives: The latent reservoir for HIV-1 in resting memory CD4+ T cells is a major barrier to eradication. In vitro models involving transformed cell lines have been used to search for small molecules that reactivate latent HIV-1. Histonedeacetylase(HDAC) inhibitors canreverse HIV-1 latent infection. MoststudiesonHDACinhibitors have been performed in cell line models that differ in important aspects fromthe resting CD4+Tcells that harbour latent HIV- 1 in vivo. Therefore, we evaluated the potency and kinetics of HDAC inhibitors in a primary cell model of HIV-1 latency that involves resting CD4+ T cells. Methods: A green fluorescent protein (GFP)-expressing reporter virus NL4-3-δ6-drGFPwas used to generate latent infection in Bcl-2-transduced primary CD4+ T cells. Seventeen HDAC inhibitors were tested in this primary cell model. The effects of these HDAC inhibitors on the reactivation of latent HIV-1 were determined and compared with anti-CD3 and anti-CD28 co-stimulation. Results: In Bcl-2-transduced primary CD4+ T cells, short-term treatment with HDAC inhibitors resulted in very limited reactivation of latent HIV-1, while prolonged treatment greatly enhanced drug efficacy. The effects of HDAC inhibitors in reactivating latent HIV-1 correlated with their inhibitory effects on class I HDACs. Importantly, HIV-1 reactivated by HDAC inhibitors can quickly re-establish latent infection upon drug removal. Conclusions:We identified unique features of HDAC inhibitor-induced reactivation of latent HIV-1 in primary CD4+ T cells. Our findings may be useful for the design of eradication trials.
机译:目的:静息记忆CD4 + T细胞中HIV-1的潜在储存库是根除的主要障碍。涉及转化细胞系的体外模型已用于寻找可重新激活潜在HIV-1的小分子。组蛋白去乙酰化酶(HDAC)抑制剂可以逆转HIV-1潜伏感染。 HDAC抑制剂的大多数研究已在细胞系模型中进行,这些模型在重要方面与体内携带潜在HIV-1的静息CD4 + T细胞有所不同。因此,我们在涉及静息CD4 + T细胞的HIV-1潜伏期的原代细胞模型中评估了HDAC抑制剂的效价和动力学。方法:使用表达绿色荧光蛋白(GFP)的报告基因病毒NL4-3-δ6-drGFP在Bcl-2转导的原代CD4 + T细胞中产生潜伏感染。在该原代细胞模型中测试了十七种HDAC抑制剂。确定了这些HDAC抑制剂对潜在HIV-1激活的影响,并与抗CD3和抗CD28共刺激进行了比较。结果:在Bcl-2转导的原代CD4 + T细胞中,用HDAC抑制剂进行的短期治疗导致潜伏HIV-1的再激活非常有限,而延长的治疗则大大提高了药物疗效。 HDAC抑制剂在重新激活潜在HIV-1中的作用与其对I类HDAC的抑制作用相关。重要的是,被HDAC抑制剂激活的HIV-1可以在去除药物后迅速重新建立潜在感染。结论:我们鉴定了HDAC抑制剂诱导的原代CD4 + T细胞中潜在HIV-1再活化的独特特征。我们的发现可能对根除试验的设计有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号